title: Correlations of plasma and urinary phenylacetic acid and phenylethylamine concentrations with eating behavior and mood rating scores in brofaromine-treated women with bulimia nervosa.
abstract: Women with bulimia nervosa undergoing treatment with the reversible monoamine oxidase type A inhibitor, brofaromine, were rated for mood and eating behaviour and their plasma and urine were assessed for phenylacetic acid (unconjugated and total) and unconjugated phenylethylamine prior to and after four weeks of drug treatment. Changes in plasma unconjugated phenylacetic acid concentrations were significantly and negatively correlated with the corresponding changes in Hamilton Depression scores but not with eating behavior measures. There were no significant correlations between changes in phenylethylamine levels and changes in rating scores. Patients diagnosed as suffering concurrently from severe depression (Hamilton Depression score of 17 or higher) had lower plasma and urinary phenylacetic acid levels than did those whose depression was not severe (Hamilton score less than 17). Phenylethylamine concentrations were not different between the severely and mildly depressed subgroups. The results confirm earlier studies on the relationship between phenylacetic acid and depression while showing that a similar relationship does not pertain to phenylacetic acid and eating behavior in bulimia nervosa.
authors.affiliation: Neuropsychiatric Research Unit, University of Saskatchewan, Saskatoon.
authors.forename: B A
authors.initials: BA
authors.lastname: Davis
authors.forename: S H
authors.initials: SH
authors.lastname: Kennedy
authors.forename: J
authors.initials: J
authors.lastname: D'Souza
authors.forename: D A
authors.initials: DA
authors.lastname: Durden
authors.forename: D S
authors.initials: DS
authors.lastname: Goldbloom
authors.forename: A A
authors.initials: AA
authors.lastname: Boulton
mesh_terms: D000328:Adult; D002032:Bulimia / Q000188:drug therapy*; D003866:Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000097:blood* / Q000652:urine*; D010648:Phenylacetates / Q000097:blood* / Q000652:urine*; D010880:Piperidines / Q000627:therapeutic use*; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D012720:Severity of Illness Index; D016037:Single-Blind Method
chemical_list: D008996:Monoamine Oxidase Inhibitors; D010648:Phenylacetates; D010880:Piperidines; D010919:Placebos; C038213:brofaromine; C025136:phenylacetic acid